Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study
Authors' conclusion
Among this real-world sample, GLP-1 use was associated with more modest weight loss than has been demonstrated in randomized controlled trials.
Study context
- Population
- Individuals aged ≥18 years with continuous GLP-1 RA use, September 2014–November 2023, TriNetX electronic health records
- Participants
- 78,076 / 23,861 / 12,642
- Exposure
- Duration of continuous GLP-1 RA use (3, 6, 9 months); discontinuers vs continuing counterparts
- 3 monthsn = 78,076
- 6 monthsn = 23,861
- 9 monthsn = 12,642
- Outcome
- Change in BMI with GLP-1 RA use and after discontinuation
Methodological detailselectronic health records (TriNetX), intention-to-treat framework, linear mixed effects models, propensity score adjustment
- Electronic health records (TriNetX)
- Intention-to-treat framework
- Linear mixed effects models
- Propensity score adjustment
Main finding
As reported in the abstract
Median BMI decline from pre-initiation
3 months
2.15%
median · IQR 2.10%–2.21%
6 months
4.38%
median · IQR 4.27%–4.48%
9 months
5.56%
median · IQR 5.34%–5.78%
Observational data: associations, not effects.
Further findings
- BMI before initiation and after 3 months of use
- 35.81 · median · IQR 35.7–35.92
Weight loss after discontinuation · months 3, 6 and 9
- On average, weight loss among discontinuers at months 3, 6 and 9 slowed vs counterparts
Original publication
Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study. Obesity (Silver Spring). Published 21 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →